Arrowhead Research | ARWR - Current Assets

Stock Price
63.59
Daily Change
-0.27 -0.42%
Monthly
-5.93%
Yearly
219.55%
Q1 Forecast
61.62

Arrowhead Research reported $1.17B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Anika Therapeutics USD 101.59M 2.27M Sep/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
Heron Therapeutics USD 229.4M 18.48M Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
Ligand Pharmaceuticals USD 753.92M 400.98M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Moderna USD 6.54B 54M Dec/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
TG Therapeutics USD 599.76M 64.2M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025
Xencor USD 518.44M 5.29M Sep/2025